ORPH实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (1 Jan 1970 @ 08:00):

Stats
今日成交量	941 412
平均成交量	1.38M
市值	0.00
EPS	$0 ( 2022-04-05 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.227
ATR14	$0.157 (18.05%)

Insider Trading

Date	Person	Action	Amount	type
2005-04-18	Orbimed Advisors Llc	Buy	0	Not reporting securities information.
2004-06-30	Stahl Pamela J	Buy	17 500	Stock Option (Right to Buy)
2004-06-15	Champsi Farah	Buy	5 000	Non-employee Director Stock Options (Right to Buy)
2004-06-15	Vida Julius A	Buy	5 000	Non-employee Director Stock Option (Right to Buy)

INSIDER POWER
0.00
Last 3 transactions
Buy: 27 500 \| Sell: 0

音量相关性

長: -0.13 (neutral)

短: 0.26 (neutral)

Signal:(38.295) Neutral

Orphazyme A/S 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Orphazyme A/S 相关性 - 货币/商品

0.20
( neutral )

-0.67
( moderate negative )

-0.39
( neutral )

-0.17
( neutral )

0.07
( neutral )

-0.26
( neutral )

Orphazyme A/S 财务报表

Annual	2020
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-22.32

FY	2020
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-22.32

FY	2019
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-16.87

FY	2018
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-11.50

Financial Reports:

No articles found.

Orphazyme A/S

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.